This week in aesthetics, we highlight the 2021 injectable pipeline, dermatology practice cybersecurity, and more.
This week in aesthetics, Gabriella DiMarco, MD, debunks hair loss treatment myths, Brian S. Biesman, MD, and Michael H Gold, MD, discuss the 2021 injectable pipeline, Gary Salman explains how to protect the practice from cybercrime, and ASDSA issues a patient safety alert after children inject HA via “hyaluron pens”.
Aesthetic providers should guide patients toward treatments for hair loss with a long track record of efficacy and away from those with little scientific support.
Brian S. Biesman, MD, and Michael H. Gold, MD, discuss the state of injectables in 2021, including renewed interest in biostimulators, and dermal fillers hitting the U.S. market.
Physicians discuss 2021 neurotoxin FDA-approvals, phase 3 trials, new indications, and introductions into the U.S. market.
Gary Salman discusses how to protect the practice from cybercriminals, plus the risks of not having cybersecurity measures in place.
ASDSA has issued a patient safety alert after videos surface online of children/teens self-injecting HA via “hyaluron pens”.